MDM2 and neoplasm: Co-treatment with Nutlin-3 and Bcl-2 inhibitor ABT-737 has been shown to greatly enhance the sensitivity to apoptosis of cancer cells with high MDM2 levels [153], suggesting that the combined inhibition of MDM2 and Bcl-2 could be a multi-target-based anticancer strategy to trigger tumor death [154].